Replies to post #76654 on $heff's $tation of $tocks & $olid DD

[pmony5]

ADMP Briefing just out. Adamis Pharma initiated with a Buy at CRT Capital; tgt $15 (6.68)
CRT Capital initiates ADMP with a Buy and target of $15. Having recently acquired the exclusive rights to 3M's multi-dose dry powder inhaler (DPI), CRT believes there is the potential for Adamis to develop a competing product to GSK's Advair Diskus by 2017. Adamis intends to use the 505(b)2 regulatory pathway, which could cut down on the development costs, and shorten the time to market. Adamis plans on beginning clinical trials for its dry powder inhaler (named APC-5000) in mid-14. CRT believes ADMP shares could benefit as the Co moves into clinical trials with 2 of its 3 respiratory treatments in 2014.